The core aim of this project is to identify novel biomarkers in blood from NAFLD (non-alcoholic fatty liver disease) and NASH (non-alcoholic steatohepatitis) patients using a technology based on an entirely new approach named APTASHAPE, which enables an unbiased and high throughput method for identifying alterations in protein composition in the blood during onset, development and treatment of disease. 

Currently, liver biopsy is the only reliable diagnostic approach for patients with NAFLD and NASH. It is an invasive and potentially dangerous procedure for the patients due to the risk of bleeding. Thus, a large unmet clinical need exists for new blood biomarkers to diagnose and stage patients with NAFLD and NASH, and for monitoring treatment response.

Participants:

• Professor Jørgen Kjems, iNANO/Department of Molecular Biology and Genetics
• Professor Henning Grønbæk, Department of Clinical Medicine
• Associate Professor Christian Bjerggaard Vægter, Department of Biomedicine
• Natasha Barascuk Michaelsen, Novo Nordisk A/S